Zydus Lifesciences gets USFDA nod for generic cholesterol lowering drug

Zydus Lifesciences Ltd. has secured final USFDA approval to manufacture generic Niacin extended-release tablets in 500 mg, 750 mg, and 1,000 mg strengths. These tablets, produced in Ahmedabad, address elevated cholesterol and triglycerides, reducing the risk of myocardial infarction. The US market for these tablets has annual sales of USD 5.5 million, according to IQVIA MAT February 2025 data.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JsOMtPg
via IFTTT